Day One Biopharmaceuticals Director John A. Josey Exits All Equity in Servier Cash Merger

Context The Servier acquisition took Day One private at a fixed cash price of $21.50 per share. The deal valued the company at roughly $1.0 billion, based on an estimated 48 million shares outstanding before the merger. DAWN’s stock had closed at $18.86 on April 22, 2026, meaning the offer represented a 14 % premium to the prior day’s price and triggered a 12 % rise in the shares on the day of the announcement.

Key Facts Josey’s 72,292 common shares were exchanged for cash at $21.50 per share, totaling about $1.55 million. His 15,000 restricted stock units and several fully vested stock option grants—covering tens of thousands of shares with exercise prices of $7.01 and $8.99—were canceled and paid out in cash equal to the merger consideration, less any applicable exercise price for options. Following these transactions, his Form 4 shows zero remaining common stock or derivative holdings.

What It Means The cash‑out eliminates Josey’s direct financial interest in Day One, aligning his incentives with the post‑merger integration under Servier. For investors, the transaction removes a potential source of insider selling and signals a clean exit for the director. Observers should watch how Servier integrates Day One’s pipeline, particularly its lead oncology programs, and whether any further insider transactions emerge as the combined entity reports its first quarterly results.